Globus Medical Cuts 2026 Revenue Forecast
The Pennsylvania-based spine device maker lowered its full-year sales outlook while boosting its share buyback authorization.
Updated on Nov. 12, 2026 in Healthcare

Globus Medical lowered its 2026 revenue forecast to $3.09 billion, down from a prior range of $3.18 billion to $3.22 billion. The company also authorized an additional $500 million in share repurchases after reporting a 0.7% decline in third-quarter sales.
Why it matters
The forecast cut reflects slower growth in the company's U.S. spine business and declining international sales, signaling pressure in core markets. The added buyback capacity signals management's continued confidence in returning capital to shareholders.
Enabling Technologies revenue rose 24% and robotic and navigation system deployments increased 73% year over year, while international revenue fell 5.7%. Gross profit margin reached 66.7% for the quarter, and reaffirmed adjusted diluted EPS guidance stands at $4.95 to $5.05.
The players
Globus Medical Inc.
Globus Medical is a musculoskeletal technology company headquartered in Audubon, Pennsylvania, that develops spine implants and robotic surgical navigation systems.
The details
Globus Medical reported third-quarter worldwide revenue of $763.7 million, with U.S. revenue up 0.5% and international revenue down 5.7%. The company reduced cost of sales by $19.6 million and operating expenses by $25.9 million compared with the same quarter in 2025.
Timeline
- Third quarter ended Sept. 30, 2026, the period covered by the reported results.
- Prior-year comparison period was the third quarter of 2025.
Healthcare Landscape
Growth in robotic and navigation-assisted spine surgery contrasts with slowing core U.S. spine sales for Globus Medical, showing that adoption of surgical technology is outpacing the company's traditional implant business. The divergence points to a shift in how the company is earning growth within the orthopedic device sector.
For patients weighing spine surgery, the expanding use of robotic and navigation systems may affect procedure options at hospitals that adopt them. Investors tracking the company should note the reaffirmed earnings range alongside the lower revenue outlook.
The takeaway
Globus Medical's results show that growth is increasingly coming from surgical technology rather than implant sales alone. Readers following medical device earnings can watch whether robotic adoption offsets softness in U.S. and international spine markets.
Further reading
For more on the state's medical sector, see Healthcare coverage across Pennsylvania.
Source note: This article includes information reported by MyChesCo.










